Stream
Stories
-
Shanghai Henlius Biotech registers Phase II/III study of HLX37 in first-line NSCLC
The study, first posted on ClinicalTrials.gov on October 8, 2026, plans to enroll 1438 participants and plans to begin recruiting on November 30, 2026. It compares two doses of HLX37 combined with chemotherapy to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer.
-
DBV Technologies posts results of Phase 3 Viaskin Peanut study
The REALISE study evaluated Viaskin Peanut 250 μg in 393 peanut-allergic children aged 4 to 11 years in a 6-month randomized, double-blind, placebo-controlled Phase III trial. The study began on October 25, 2016, with primary completion on September 22, 2017.
-
PTC Therapeutics posts results of Phase 3 ataluren safety study in Duchenne muscular dystrophy
Results for the open-label safety study of ataluren (PTC124) in 265 participants with nonsense mutation dystrophinopathy were first posted on ClinicalTrials.gov on October 8, 2026. The study, which began on November 22, 2010 and reached primary completion on February 10, 2026, was terminated before completion.
-
FDA approves tucatinib with trastuzumab and pertuzumab for HER2-positive breast cancer maintenance
On October 7, 2026, the FDA approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. The approval follows a randomized, double-blind, placebo-controlled trial of 654 patients that showed a median progression-free survival of 24.9 months versus 16.3 months in the placebo arm.
-
Sagimet registers Phase 3 trial of denifanstat in moderate to severe acne vulgaris
The study, first posted on ClinicalTrials.gov on October 7, 2026, plans to enroll 800 participants and begin in October 2026. After a 12-week treatment phase, about 530 participants may consent to a 40-week open-label extension.
-
Sanofi posts results of Phase 3 MenACYW conjugate vaccine study in infants and toddlers
Results for the Phase 3 study comparing MenACYW conjugate vaccine (MenQuadfi) with Nimenrix were first posted on ClinicalTrials.gov on October 7, 2026. The 840-participant, randomized, triple-masked trial, completed on November 14, 2025, evaluated non-inferiority of the immunological response after a 1+1 vaccination schedule in healthy infants and toddlers.
-
Instituto Grifols posts results of Phase II/III trial of plasma-derived AT-III concentrate
The study enrolled 3 participants with Antithrombin III Deficiency and began on April 15, 2008. It was terminated after primary completion in December 2011.
-
Pharmazz, Inc. registers Phase 3 study of sovateltide for acute traumatic brain injury
The study, titled RESTORE-TBI, plans to enroll 214 participants and is scheduled to begin in December 2026. It is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial evaluating the efficacy and safety of sovateltide (IRL-1620) in patients with traumatic brain injury.
-
GlaxoSmithKline registers Phase 3 linerixibat safety eXtension study in Japan
The study plans to enroll 40 participants and start on October 9, 2026. It aims to assess the long-term safety of linerixibat in Japanese adults with cholestatic pruritus in primary biliary cholangitis (PBC) who previously participated in the linerixibat long-term safety and efficacy study, LLSAT (NCT04167358).
-
GlaxoSmithKline posts results of Phase 3 salbutamol safety study
Results for this study were first posted on ClinicalTrials.gov on October 6, 2026, for a Phase 3 trial that enrolled 471 participants. The study began May 31, 2024 and completed primary data collection on September 2, 2025.
-
Janssen posts results of Phase 3 aticaprant study in major depressive disorder
Results for the VENTURA-LT study of aticaprant (JNJ-67953964) were first posted on October 6, 2026. The open-label, long-term safety and efficacy study enrolled 871 participants, started on September 22, 2022, and completed primary data collection on April 25, 2025.
-
Vascular Therapies posts results of Phase 3 ACCESS 2 trial of Sirogen in ESRD patients
The ACCESS 2 trial, a Phase 3 study with 136 participants, evaluated the Sirolimus eluting Collagen implant (Sirogen) in patients undergoing arteriovenous fistula surgery. Results were first posted on ClinicalTrials.gov on October 6, 2026, after the study's primary completion on March 18, 2025.